European Psychiatry - Volume 33 - March 2016

291 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348 S287
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW493
Medication and aggressiveness in
real-world schizophrenia. Results
from the FACE-SZ dataset
G. Fond Favez oyer ierre-Michel elissol
F. Berna ∗
1 Schizophrenia expert, center Fondation fondamental, Creteil, France
2 Pôle psychiatrie universitaire - CHU Sainte-Marguerite, pôle
psychiatrie universitaire, Marseille, France
3 Schizophrenia expert, center Fondation fondamental,
Clermont-Ferrand, France
4 Hôpitaux universitaires de Strasbourg- Inserm U1114- FMTS-
Fondation FondaMental, psychiatry, Strasbourg cedex, France
∗ Corresponding author.
Introduction The primary objective of this study was to deter-
mine if second generation antipsychotic (SGA) administration was
associated with lower aggressiveness scores compared to first gen-
eration (FGA) in schizophrenia (SZ). The secondary objective was
to determine if antidepressants, mood stabilizers and benzodi-
azepines administration were respectively associated with lower
aggressiveness scores compared to patients who were not admin-
istered these medications.
Methods Three hundred and thirty-one patients with
schizophrenia (n = 255) or schizoaffective disorder (n = 76) (mean
age = 32.5 years, 75.5% male gender) were systematically included
in the network of FondaMental Expert Center for Schizophrenia
and assessed with the Structured Clinical Interview for DSM-IV
Axis I Disorders and validated scales for psychotic symptomato-
logy, insight and compliance. Aggressiveness was measured by
the Buss-Perry Aggression Questionnaire (BPAQ) score. Ongoing
psychotropic treatment was recorded.
Results Patients who received SGA had lower BPAQ scores than
patients who did not (P= 0.01). On the contrary, patients who
received benzodiazepines had higher BPAQ scores than patients
who did not (P = 0.04). These results were found independently
of socio-demographical variables, psychotic symptomatology,
insight, compliance into treatment, daily-administered antipsy-
chotic dose, the way of antipsychotic administration (oral vs long
acting), current alcohol disorder and daily cannabis consumption.
Conclusion The results of the present study are in favor of
the choice of SGA in SZ patients with aggressiveness, but these
results need further investigation in longitudinal studies. Given
the potent side effects of benzodiazepines (especially dependency
and cognitive impairment) and the results of the present study,
their long-term prescription is not recommended in patients with
schizophrenia and aggressive behavior.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW494
Emotional recognition during the
course of schizophrenia
D. Boˇsnjak ∗, P. Makari´c , M. Rojni´c Kuzman
1 University psychiatric hospital Vrapce, The Addictions Department,
Zagreb, Croatia
2 University psychiatric hospital Vrapce, The Department for
Diagnostics and Intensive Care, Zagreb, Croatia
3 Zagreb university hospital centre, department of psychiatry, Zagreb,
Croatia
∗ Corresponding author.
Introduction Adequate emotion identification ability facilitates
forming emotional relationships and effective communication.
Patients suffering from schizophrenia have deficits in emotional
recognition (ER), which leads to impaired social and occupational
functioning.
Objectives To compare the differences in ER between the healthy
control group (HC) and two patient groups at different phases of
illness: first episode psychosis (FEP) and chronic, multi-episode
schizophrenia (MEP).
Aims To investigate the pattern of emotional recognition deficit
during the course of schizophrenia.
Methods We compared three groups of participants: MEP, FEP
and HC, each containing 50 participants, based on their emo-
tional recognition abilities using the Penn Emotion Recognition
Task and The I FEEL Pictures. Patients were diagnosed using Diag-
nostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5) criteria for schizophrenia (schizophreniform disorder)
with their psychopathology rated with the Positive and Negative
Syndrome Scale (PANSS) scale. Besides ER tasks, patients were
administered self-evaluation scales for the assessment of quality
of life, depression, suicidality, impulsivity, aggression, and relation-
ship with their parents.
Results Our findings showed deficits in emotional recognition
ability of both patient groups in comparison with HC, especially
in the identification of negative emotions: sadness, fear and anger.
There was no statistically significant difference between groups in
the identification of happiness. First episode patients showed better
results than the MEP group.
Conclusions Although the FEP group was more successful than
the ME group, our results showed that the emotional recognition
impairment exists at a significant level even at the beginning of the
illness.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW495
Medication adherence and cannabis
use among schizophrenic patients
S. Bouri ∗, H. Zemmama , K. El Ayoubi , M.A. Berraho ,
A. Abdellaoui , S. Achour , I. Rammouz
1 Faculty of science- Dhar El Mahraz, laboratory physiology -
pharmacology & environmental health, Fez, Morocco
2 Faculty of medicine, clinical neurosciences laboratory, Fez, Morocco
3 Faculty of medicine, epidemiology public health, Fez, Morocco
4 Faculty of science, physiology- pharmacology-environmental
health, Fez, Morocco
5 University hospital Hassan II, toxicology unit, Fez, Morocco
∗ Corresponding author.
Introduction Substance use is usually associated with poorer
psychiatric medication adherence among schizophrenic patients.
Previous findings remain unclear about the relationship between
cannabis use and poor medication adherence. Identifying pre-
dictor factors of medication adherence among these patients
is very important because it’s associated with relapse and re-
hospitalization.
Objective Determining whether cannabis use is a risk factor for
compliance tomedication in a populationof schizophrenic patients.
Method Schizophrenic inpatients were assessed by Medication
Adherence Rating Scale (MARS). Socio-demographic, clinical data,
and urine drug screens were collected just after their admission.
Results A sample of 403 inpatientswith schizophrenia diagnosed
withDiagnostic and Statistical Manual of Mental Disorders, 4th Edi-
tion (DSM-IV) criteria (mean age = 33, 35 ±9, 16), predominantly
man (90%), paranoid (62%) and 89% of them received classical
antipsychotics. A total of (n = 25; 6, 2%) inpatients were adher-
ent, among this group, 19 patients (76%) were tested negative for